The New Jersey Prescription Monitoring Program
(NJPMP) is an important component of the New Jersey Division of Consumer Affairs'
(Division) effort to halt the abuse and diversion of prescription drugs.
The NJPMP, established pursuant to
N.J.S.A. 45:1-45 et. seq., is a statewide database that collects prescription data on Controlled Dangerous Substances
(CDS), Human Growth Hormone (HGH) and gabapentin dispensed in outpatient settings in New Jersey, and by out-of-State pharmacies dispensing into New Jersey.
Access to the NJPMP is granted to prescribers and pharmacists who are licensed by the State of New Jersey and are in good standing with their respective licensing boards. Registered prescribers may delegate their authority to access the NJPMP to certain other healthcare professionals.
Patient information in the NJPMP is intended to help prescribers and pharmacists provide better-informed patient care. The information will help supplement patient evaluations, confirm patient drug histories, and document compliance with therapeutic regimens. When prescribers, delegates, or pharmacists identify a patient as potentially having an issue of concern regarding drug use, they are encouraged to help the patient locate assistance and take any other action the prescriber or pharmacist deems appropriate.
The NJPMP also serves as an effective tool for identifying those who fraudulently obtain prescription drugs or are otherwise involved in the criminal diversion of prescription medication.
The information reported to and made available through the NJPMP will help detect individuals who may be "doctor shopping" – visiting multiple prescribers to obtain prescriptions for the same medications that they then have filled at different pharmacies to obtain more of the prescribed substance than any one physician or pharmacist would allow.
The NJPMP will also aid in detecting "pill mills" – a prescriber's office, clinic, or other healthcare facility that regularly colludes in the prescribing and dispensing of controlled substances outside the scope of the prevailing standards of care, and in violation of New Jersey law on the prescribing and dispensing of controlled substances.